Literature DB >> 32696297

Engineering the gut microbiota to treat chronic diseases.

Noura S Dosoky1, Linda S May-Zhang1, Sean S Davies2.   

Abstract

Gut microbes play vital roles in host health and disease. A number of commensal bacteria have been used as vectors for genetic engineering to create living therapeutics. This review highlights recent advances in engineering gut bacteria for the treatment of chronic diseases such as metabolic diseases, cancer, inflammatory bowel diseases, and autoimmune disorders. KEY POINTS: • Bacterial homing to tumors has been exploited to deliver therapeutics in mice models. • Engineered bacteria show promise in mouse models of metabolic diseases. • Few engineered bacterial treatments have advanced to clinical studies.

Entities:  

Keywords:  Atherosclerosis; Cancer; Diabetes; Engineered bacteria; Gut microbiota; Inflammatory bowel disease; Obesity

Mesh：

Year:  2020        PMID： 32696297      PMCID： PMC7484268          DOI： 10.1007/s00253-020-10771-0

Source DB:  PubMed          Journal:  Appl Microbiol Biotechnol        ISSN： 0175-7598            Impact factor:   4.813


  130 in total

Review 1.  Engineered bacteria as therapeutic agents.

Authors:  Carlos Piñero-Lambea; David Ruano-Gallego; Luis Ángel Fernández
Journal:  Curr Opin Biotechnol       Date:  2015-06-09       Impact factor: 9.740

2.  Killed Bacillus subtilis spores expressing streptavidin: a novel carrier of drugs to target cancer cells.

Authors:  Van Anh Thi Nguyen; Hong Anh Huynh; Tong Van Hoang; Ngoc Thi Ninh; An Thi Hong Pham; Hoa Anh Nguyen; Tuan-Nghia Phan; Simon M Cutting
Journal:  J Drug Target       Date:  2013-03-12       Impact factor: 5.121

3.  Combination bacteriolytic therapy for the treatment of experimental tumors.

Authors:  L H Dang; C Bettegowda; D L Huso; K W Kinzler; B Vogelstein
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-27       Impact factor: 11.205

Review 4.  Gut microbiota, metabolites and host immunity.

Authors:  Michelle G Rooks; Wendy S Garrett
Journal:  Nat Rev Immunol       Date:  2016-05-27       Impact factor: 53.106

5.  Combined effect of improved cell yield and increased specific productivity enhances recombinant enzyme production in genome-reduced Bacillus subtilis strain MGB874.

Authors:  Kenji Manabe; Yasushi Kageyama; Takuya Morimoto; Tadahiro Ozawa; Kazuhisa Sawada; Keiji Endo; Masatoshi Tohata; Katsutoshi Ara; Katsuya Ozaki; Naotake Ogasawara
Journal:  Appl Environ Microbiol       Date:  2011-09-30       Impact factor: 4.792

6.  Anticancer efficacy of systemically delivered anaerobic bacteria as gene therapy vectors targeting tumor hypoxia/necrosis.

Authors:  S C Liu; N P Minton; A J Giaccia; J M Brown
Journal:  Gene Ther       Date:  2002-02       Impact factor: 5.250

Review 7.  Salmonella-Mediated Cancer Therapy: An Innovative Therapeutic Strategy.

Authors:  Ze Mi; Zhi-Chao Feng; Cheng Li; Xiao Yang; Meng-Tian Ma; Peng-Fei Rong
Journal:  J Cancer       Date:  2019-08-20       Impact factor: 4.207

8.  A new plasmid vector for DNA delivery using lactococci.

Authors:  Valeria Guimarães; Sylvia Innocentin; Jean-Marc Chatel; François Lefèvre; Philippe Langella; Vasco Azevedo; Anderson Miyoshi
Journal:  Genet Vaccines Ther       Date:  2009-02-10

Review 9.  Role of commensal and probiotic bacteria in human health: a focus on inflammatory bowel disease.

Authors:  Rebeca Martín; Sylvie Miquel; Jonathan Ulmer; Noura Kechaou; Philippe Langella; Luis G Bermúdez-Humarán
Journal:  Microb Cell Fact       Date:  2013-07-23       Impact factor: 5.328

Review 10.  Lactococcus lactis As a Versatile Vehicle for Tolerogenic Immunotherapy.

Authors:  Dana P Cook; Conny Gysemans; Chantal Mathieu
Journal:  Front Immunol       Date:  2018-01-17       Impact factor: 7.561
View more
  8 in total

Review 1.  Altered gut microbial metabolites could mediate the effects of risk factors in Covid-19.

Authors:  Jiezhong Chen; Sean Hall; Luis Vitetta
Journal:  Rev Med Virol       Date:  2021-01-13       Impact factor: 11.043

Review 2.  Synthetic Biology Approaches in The Development of Engineered Therapeutic Microbes.

Authors:  Minjeong Kang; Donghui Choe; Kangsan Kim; Byung-Kwan Cho; Suhyung Cho
Journal:  Int J Mol Sci       Date:  2020-11-19       Impact factor: 5.923

Review 3.  Focus on the Gut-Kidney Axis in Health and Disease.

Authors:  Elisavet Stavropoulou; Konstantia Kantartzi; Christina Tsigalou; Theoharis Konstantinidis; Gioulia Romanidou; Chrysa Voidarou; Eugenia Bezirtzoglou
Journal:  Front Med (Lausanne)       Date:  2021-01-21

4.  Evolutionary Stability Optimizer (ESO): A Novel Approach to Identify and Avoid Mutational Hotspots in DNA Sequences While Maintaining High Expression Levels.

Authors:  Itamar Menuhin-Gruman; Matan Arbel; Niv Amitay; Karin Sionov; Doron Naki; Itai Katzir; Omer Edgar; Shaked Bergman; Tamir Tuller
Journal:  ACS Synth Biol       Date:  2021-12-20       Impact factor: 5.110

Review 5.  Intestinal microbiota research from a global perspective.

Authors:  Jordyn T Wallenborn; Pascale Vonaesch
Journal:  Gastroenterol Rep (Oxf)       Date:  2022-04-11

6.  Ae1/Sbe1 maize-derived high amylose improves gut barrier function and ameliorates type II diabetes in high-fat diet-fed mice by increasing Akkermansia.

Authors:  Weiwei Qi; Jingchao Liu; Tante Yu; Shengchan Huang; Rentao Song; Zhenyi Qiao
Journal:  Front Nutr       Date:  2022-09-29

Review 7.  Gut Microbiota: A Key Regulator in the Effects of Environmental Hazards on Modulates Insulin Resistance.

Authors:  Ruixue Huang
Journal:  Front Cell Infect Microbiol       Date:  2022-01-17       Impact factor: 5.293

Review 8.  Bifidobacterium Longum: Protection against Inflammatory Bowel Disease.

Authors:  Shunyu Yao; Zixi Zhao; Weijun Wang; Xiaolu Liu
Journal:  J Immunol Res       Date:  2021-07-23       Impact factor: 4.818
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.